New Delhi: A study conducted by researchers at Fortis Escorts Heart Institute, New Delhi has demonstrated the superiority of Everolimus eluting stents over Paclitaxel eluting stents in patients with diabetes mellitus and coronary artery disease.
According to the researchers, the single blind randomized clinical trial was conducted on 1830 patients at 46 Indian hospitals. The study findings appear online in the New England Journal of Medicine (NEJM).
“In recent times, India has emerged as the capital for diabetes with a large population effected by this insidious disease. These findings will enable doctors to provide an informed view to their patients and help to improve outcomes, especially in the case of diabetic patients,” according to lead researcher Dr Upendra Kaul, dean and executive director, cardiology, Fortis Escorts Heart Institute, New Delhi.
“It is a path-breaking research that clearly demonstrated the superiority of one stent over another in diabetics,” Dr Ashok Seth, chairman, Fortis Escorts Heart Institute, New Delhi, told India Medical Times.
He further said, “Diabetics is a difficult area and we are looking for best stents for that. The study was done at our own institute on certain patients, which showed the superiority of Everolimus eluting stents over Paclitaxel eluting stents. The first good thing is that Everolimus is good for diabetes and second reason is that it has shown better outcome than that of Paclitaxel eluting stents. I would say quite better results. There are no complications in it. We have certified it on patients with diabetes mellitus and coronary artery disease.”
“Our study also puts a question mark on previous studies that bypass surgery would be better but the new drug eluting stents in patients with diabetes showed outcomes were superior, including significantly lower all-cause mortality. It is a landmark achievement,” added Dr Seth, who is also a part of the team conducting the study.